Physician profile
John H Hall
NPI 1174610935
$652.99
in general payments reported to CMS, 2019-2025
12 companies · $78.55 in 2025
The $78.55 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.00 · 2020: $28.45 · 2021: $41.43 · 2022: $83.27 · 2023: $213 · 2024: $137 · 2025: $78.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.58 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $200.17 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Biotech, INC. | $171.99 | 2019-2023 | Tremfya |
| Esperion Therapeutics, INC. | $42.22 | 2022-2023 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.63 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $36.22 | 2025 | Hetlioz, Fanapt |
| Pfizer INC. | $30.39 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $29.96 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $27.21 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.21 | 2022 | |
| Glaxosmithkline, LLC. | $18.48 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $16.68 | 2022 | |
| Novo Nordisk INC | $15.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.